Michelle is a credit expert, freelance writer and founder of CreditWriter.com. She has over 20 years of experience writing and speaking about credit and money, and focuses on helping families and ...

Casgevy and Lyfgenia, the two cell-based gene therapies approved by the FDA, utilise the CRISPR/Cas9 genome editing technology. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR ...

The biotech's Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed with Vertex Pharmaceuticals, is now approved in the U.S ...

This latest gene therapy offering is Casgevy, which treats sickle cell disease and transfusion-dependent beta thalassemia, a blood disorder that reduces the production of hemoglobin.

The company is anticipating continued growth in fiscal 2025 with the approval of JOURNAVX, the launch of its fifth CF medicine, ALYFTREK, and the continuing global acceptance of CASGEVY ...

Casgevy, which carries a $2.2 million list price, won FDA approval in December 2023 to treat sickle cell disease, and a month later received agency authorization to treat transfusion-dependent ...

Vertex is still in the early stages of the commercial launch of Casgevy, a one-time treatment for sickle cell disease and transfusion-dependent beta-thalassemia. The company now has more than 50 ...

What Casgevy does is turn a patient’s own cells, already a perfect match, into a transplant. Doctors harvest stem cells from the patient’s bone marrow and then send them off to a lab ...

That approval was announced concurrent with the regulatory nod for Casgevy, a Vertex Pharmaceuticals gene therapy for the same indication. Casgevy’s approval did come with a PRV. Financial ...

These treatments, however, are complex and expensive. CAR-T therapy costs approximately $500,000, while Casgevy is priced at $2.2 million. Although these therapies can prevent suffering and save ...

"We believe Casgevy expectations have bottomed out in the near term and CRISPR should get some platform value," the bank said in a note, adding it was unclear at this time which pipeline asset ...